Table I.
Patient Demographics at Baseline
| With T2DM (n=254)* | Without T2DM (n=590) | With the Metabolic Syndrome (n=386)** | Without the Metabolic Syndrome (n=449)** | With T2DM and the Metabolic Syndrome (n=177) | |
|---|---|---|---|---|---|
| Mean age (yr) | 58.2 | 56.9 | 55.3 | 59.0 | 56.7 |
| Women (n [%]) | 112 (44) | 324 (55) | 213 (55) | 217 (48) | 87 (49) |
| Men (n [%]) | 142 (56) | 266 (45) | 173 (45) | 232 (52) | 90 (51) |
| Race/ethnic group (n [%])† | |||||
| Caucasian | 153 (60) | 362 (61) | 246 (64) | 262 (58) | 112 (63) |
| African American | 48 (19) | 143 (24) | 72 (19) | 117 (26) | 31 (18) |
| Hispanic/Latino | 50 (20) | 69 (12) | 64 (17) | 55 (12) | 33 (19) |
| Other | 3 (1) | 18 (3) | 6 (2) | 15 (3) | KD |
| Previous antihypertensive monotherapy (n [%]) | |||||
| β Blocker | 28 (11) | 69 (12) | 51 (13) | 46 (10) | 21 (12) |
| α Blocker | 4 (2) | 7 (1) | 4 (1) | 7 (2) | 2 (1) |
| Calcium channel blocker | 35 (14) | 133 (23) | 65 (17) | 101 (22) | 26 (15) |
| Angiotensin receptor blocker | 38 (15) | 128 (22) | 65 (17) | 99 (22) | 25 (14) |
| Angiotensin‐converting enzyme inhibitor | 118 (46) | 165 (28) | 141 (37) | 139 (31) | 84 (47) |
| Diuretic | 29 (11) | 85 (14) | 59 (15) | 53 (12) | 18 (10) |
| Other | 4 (2) | 9 (1) | 5 (1) | 8 (2) | 3 (2) |
| *Includes 177 patients with concomitant type 2 diabetes mellitus (T2DM) and the metabolic syndrome; **metabolic syndrome status of nine patients unknown; †patients could self‐identify into more than one race/ethnic group | |||||